Reviewing MindWalk (NASDAQ:HYFT) & Fortrea (NASDAQ:FTRE)

Fortrea (NASDAQ:FTRE) and MindWalk (NASDAQ:HYFT) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, analyst recommendations, risk, dividends, earnings, institutional ownership and profitability.

Valuation & Earnings

This table compares Fortrea and MindWalk”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fortrea	$2.68 billion	0.74	-$986.20 million	($0.91)	-22.90
MindWalk	$11.24 million	6.21	-$10.11 million	($0.26)	-5.75

MindWalk has lower revenue, but higher earnings than Fortrea. Fortrea is trading at a lower price-to-earnings ratio than MindWalk, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Fortrea and MindWalk’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Fortrea	-3.18%	10.72%	2.17%
MindWalk	-105.11%	-133.26%	-77.78%

Insider and Institutional Ownership

6.7% of MindWalk shares are owned by institutional investors. 0.7% of Fortrea shares are owned by company insiders. Comparatively, 6.8% of MindWalk shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current recommendations for Fortrea and MindWalk, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fortrea	1	5	6	0	2.42
MindWalk	1	1	2	1	2.60

Fortrea currently has a consensus price target of $22.10, indicating a potential upside of 6.05%. MindWalk has a consensus price target of $5.00, indicating a potential upside of 234.45%. Given MindWalk’s stronger consensus rating and higher probable upside, analysts clearly believe MindWalk is more favorable than Fortrea.

Risk and Volatility

Fortrea has a beta of 1.93, indicating that its stock price is 93% more volatile than the S&P 500. Comparatively, MindWalk has a beta of 0.77, indicating that its stock price is 23% less volatile than the S&P 500.

Summary

MindWalk beats Fortrea on 9 of the 15 factors compared between the two stocks.

About Fortrea

Fortrea Holdings Inc., a contract research organization, primarily engages in the provision of biopharmaceutical product and medical device development services worldwide. The company operates through two segments: Clinical Services and Enabling Services. The Clinical Services segment provides across the clinical pharmacology and clinical development spectrum. The Enabling Services segment provides patient access and clinical trial technology solutions to customers that streamline complex randomization and optimize the trial drug supply process. The company offers delivery models that include full service, functional service provider, and hybrid service structures. It also offers phase I-IV clinical trial management, differentiated technology enabled trial solutions, and post approval services, as well as consulting services. The company serves pharmaceutical, biotechnology, and medical device organizations. Fortrea Holdings Inc. was incorporated in 2023 and is headquartered in Durham, North Carolina.

About MindWalk

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and related services in the United States, Canada, Europe, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multi-species antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing; antibody characterization on label-free biosensors and antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with multiplexed, high-throughput screening, and clone-picking; and cryopreservation. The company has research collaboration agreements with Pierre Fabre S.A for antibody discovery; and Elektrofi, Inc. to explore a high-concentration formulation of COVID-19 antibody cocktail, PolyTope TATX-03. ImmunoPrecise Antibodies Ltd. was incorporated in 1983 and is based in Victoria, Canada.